Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas
- Registration Number
- NCT00038701
- Lead Sponsor
- M.D. Anderson Cancer Center
- Brief Summary
The goal is to assess survival and patterns of failure in patients treated with Gemzar-based chemoradiation and TNP-470 for locally advanced adenocarcinoma of the pancreas.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Gemzar Chemoradiation + TNP-470 TNP-470 -
- Primary Outcome Measures
Name Time Method Patient Survival Rate 2 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie TNP-470's anti-angiogenic effects in pancreatic adenocarcinoma chemoradiation?
How does gemcitabine-based chemoradiation with TNP-470 compare to FOLFIRINOX in locally advanced pancreatic cancer outcomes?
Which biomarkers correlate with improved survival in NCT00038701 pancreatic cancer chemoradiation trial?
What are the most common adverse events associated with TNP-470 combination therapy in pancreatic cancer patients?
Are there alternative anti-angiogenic agents like bevacizumab that show better synergy with gemcitabine in pancreatic cancer treatment?
Trial Locations
- Locations (1)
UT MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
UT MD Anderson Cancer Center🇺🇸Houston, Texas, United States